DESENVOLVIMENTO MEDICAMENTOS BIOLÓGICOS : DESAFIOS E OPORTUNIDADES

Transcription

1 DESENVOLVIMENTO MEDICAMENTOS BIOLÓGICOS : DESAFIOS E OPORTUNIDADES HERALDO MARCHEZINI CEO BIOMM S.A. I N OVA Ç Ã O E M FÁ R M A C O S E M E D I C A M E N TO S N O B R A S I L : A N ECESSIDA D E D E I N T E R A Ç Ã O E N T R E U N I V E R S I DA D E S E E M P R E SA S F LO R I A N O P O L I S 2 6 S E T E M B R O D E CONFIDENCIAL 1

2 AGENDA 1.Biomm 2.Desafios Globais 3.Oportunidades 2

3 CONFIDENCIAL 3

4 4

5 Fabrica Biomm 2017 CONFIDENCIAL 5

6 AGENDA 1.Biomm 2.Desafios Globais 3.Oportunidades 6

7 Universities publishing the highest proportions of their research output in collaboration with industry Rank Institution Country Proportion of publications that are industry collaborations 1 Pohang University of Science and Technology (POSTECH) South Korea National Institute of Applied Sciences of Lyon (INSA Lyon) France China University of Petroleum China Norwegian University of Science and Technology Norway University of East Anglia UK Chalmers University of Technology Sweden Eindhoven University of Technology Netherlands Sungkyunkwan University (SKKU) South Korea Institute of Cancer Research UK CentraleSupélec France 6.18 Source: Clarivate Analytics, based on research articles and reviews indexed in the Web of Science Core Collection databases between 2007 and

8 8

9 GEN (Genetic engineering and biotech News) ranks regions based on five criteria: NIH funding Taken from the publicly available NIH RePORT database, for the current federal fiscal year, from its start on October 1, 2016, through May 23, Venture Capital (VC) funding Taken from 2016 and Q figures furnished by the publicly available MoneyTree Report. Patents Based on the number of patents containing the word biotechnology awarded since 1976 in namesake cities and suburbs where key companies are located. Lab space Based on total-size-of-market figures, in millions of square feet, furnished by the commercial real estate brokerage JLL in its U.S. Life Sciences Outlook report for Jobs Based on JLL s report. While job numbers are ranked this year compared with last year s Top 10 US Clusters list, less weight had to be given to job totals in regions where GEN has found widespread discrepancies in job figures. However, workforce size was factored in when deciding the ultimate position of a region. 9

10 #1 Boston \ Cambridge #1. Boston / Cambridge, MA A decade after then-gov. Deval Patrick (D) enacted the Massachusetts Life Sciences Initiative, his successor has yet to announce what support the state will offer the industry when the $1 billion, ten-year measure expires next year. However, Gov. Charlie Baker (R) has committed the state to growing life sciences companies through workforce development programs and funding for drug R&D. Supporting biopharma is also the goal of the region s incubators and accelerators including the first Chinese-owned bioincubator, the Qilu Boston Innovation Center (QBIC), which opened May 19. QBIC was founded by Qilu Pharmaceuticals, a $2 billion-a-year Chinese drug developer that opened within the incubator its first branch company, cancer immunotherapy developer QLB Biotherapeutics. Not surprisingly, the region leads the nation in NIH funding (2,169 awards totaling nearly $1.055 billion), lab space (19.9 million square feet), and 2016 VC funding (78 deals totaling $3.06 billion), though Boston/Cambridge finished second to the San Francisco Bay Area in Q1 with 19 deals totaling $534 million. Biopharma growth is fueling a wave of speculative lab space development in and around Boston and Cambridge; King Street Properties, for example, is building the $200 million, 145,000-square-foot 828 Winter Street adjacent to an existing lab building owned by the developer, and slated for completion in The region is also second in patents (6,496), but third in jobs with 86,235 according to JLL, though industry group Massachusetts Biotechnology Council (MassBio) reported 63,026 last year. 10

11 Aprovações FDA

12 (2017) Biopharma investment in China Nature Reviews Drug Discovery 16, (2017) 12

13 Desafios Globais Cadeia Produtiva P&D, Pesquisa Clínica, Serviços Analíticos, CMO s, CRO s, matérias primas; Financeiros Produto Novo (US$ 1 bilhão, 8-12 anos), Biosimilar (US$ milhões, 3-5 anos); Regulatórios Processos complexos e longos para a aprovação; Processo produtivo complexidade; Pessoal qualificado 13

14 AGENDA 1.Biomm 2.Desafios Globais 3.Oportunidades 14

15 CONFIDENCIAL 15

16 Global medicine spending will reach nearly $1.5 trillion by 2021 Source: IMS Market Prognosis, Oct

17 CONFIDENCIAL 17

18 18

19 SOURCE : CELLTRION WEBPAGE 19

20 CONFIDENCIAL 2 0